Journal: Oncotarget

Article Title: Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation

doi: 10.18632/oncotarget.11093

Figure Lengend Snippet: A. Growth curve of AE-hTERT cells in culture with indicated cytokines demonstrates AE-hTERT cells did not achieve cytokine independence. B. Percentage of CD235a+ cells of AE-hTERT and AE-pBabe cells from first plating of colony forming assay shows that AE-hTERT cells kept similar erythroid lineage potential as AE-pBabe cells. p value was calculated by two-tailed t -test. C. Flow cytometry analysis demonstrates that AE-hTERT cultures are able to produce CD19+ and CD10+ lymphoid cells under B-cell differentiation condition. 2 independent experiments are shown. D. Flow cytometry analysis of murine BM at 16 weeks post-transplantation indicates AE-hTERT cells maintain myeloid (CD13/33+) engraftment in immunodeficient mice. Human cell engraftment was indicated by GFP+hCD45+; two representative mice are shown.

Article Snippet: Assays were performed using MethoCult H4100 medium (StemCell Technologies) supplemented with 20% BIT, 50uM β-Mercaptoethanol, 2mM L-glutamine, 100U/mL penicillin/streptomycin, and the human cytokines Erythropoietin (EPO, 6U/mL), Granulocyte Colony Stimulating Factor (G-CSF, 10ng/mL), IL-6(20ng/mL), IL-3 (20ng/mL), and SCF (20ng/mL) (Peprotech).

Techniques: Two Tailed Test, Flow Cytometry, Cell Differentiation, Transplantation Assay

Journal: International Journal of Molecular Sciences

Article Title: Role of Nuclear-Receptor-Related 1 in the Synergistic Neuroprotective Effect of Umbilical Cord Blood and Erythropoietin Combination Therapy in Hypoxic Ischemic Encephalopathy

doi: 10.3390/ijms23052900

Figure Lengend Snippet: Experimental designs. Postnatal day 7 (P7) mice were induced with hypoxic-ischemic encephalopathy. On P14, the UCB (3 × 10 7 /kg) was injected, administered via intraperitoneal injection, and EPO (500 IU/kg) was given intraperitoneally from P14 for consecutive days. XAV939 (10 mg/kg) was given intraperitoneally from P14 for 7 consecutive days, 1 h before UCB and EPO treatment. One week after injection, the mice were sacrificed for qRT-PCR, Western blot, and microarray.

Article Snippet: UCB (3 × 10 7 /kg, intraperitoneal injection once at 7 days post-injury), EPO (LGchem, Daejeon, Korea) (500 IU/kg, intraperitoneal injection for 5 consecutive days from 7 days HIE), UCB+EPO (at the same dose and schedule as the other groups), and UCB+EPO+XAV939 (Sigma, St. Louis, MO, USA) (10 mg/kg, 5 consecutive days from 7 days HIE) were intraperitoneally administered, and PBS (5 consecutive days from 7 days HIE) was injected as a control (HIE).

Techniques: Injection, Quantitative RT-PCR, Western Blot, Microarray